Aquagenic Urticaria in an Adolescent Following COVID-19 Vaccine
Main Article Content
Keywords
Chronic Inducible Urticaria, Aquagenic Urticaria, COVID19, vaccine
Abstract
A subset of patients receiving COVID-19 vaccinations develops cutaneous reactions. The majority are delayed hypersensitivity reactions that resolve spontaneously without treatment. More rarely, cutaneous manifestations such as urticaria, vasculitis, and morbilliform eruptions have been reported. Aquagenic urticaria is a form of chronic inducible urticaria caused by skin contact with water. Characteristic 1-2mm folliculopapular urticarial papules appear 20-30 minutes following water exposure and spontaneously resolve within 30-60 minutes of water removal. A water provocation test is the gold standard of diagnosis. The mainstay of treatment is 2nd generation H1 antihistamines taken before water exposure. We report the development of aquagenic urticaria in a 12-year-old African American male patient following the Pfizer-BioNTech mRNA COVID-19 vaccine.
References
2. Qaderi K, Golezar MH, Mardani A, et al. Cutaneous adverse reactions of COVID‐19 vaccines: A systematic review. Dermatol Ther. 2022;35(5):e15391. doi:10.1111/dth.15391
3. Bellinato F, Maurelli M, Gisondi P, Girolomoni G. Cutaneous Adverse Reactions Associated with SARS-CoV-2 Vaccines. J Clin Med. 2021;10(22):5344. doi:10.3390/jcm10225344
4. Robinson LB, Fu X, Hashimoto D, et al. Incidence of Cutaneous Reactions After Messenger RNA COVID-19 Vaccines. JAMA Dermatol. 2021;157(8):1000-1002. doi:10.1001/jamadermatol.2021.2114
5. McMahon DE, Amerson E, Rosenbach M, et al. Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: A registry-based study of 414 cases. J Am Acad Dermatol. 2021;85(1):46-55. doi:10.1016/j.jaad.2021.03.092
6. Thomas J, Thomas G, Chatim A, Shukla P, Mardiney M. Chronic Spontaneous Urticaria After COVID-19 Vaccine. Cureus. 13(9):e18102. doi:10.7759/cureus.18102
7. Alflen C, Birch K, Shilian R, Wu SS, Hostoffer R. Two Cases of Well Controlled Chronic Spontaneous Urticaria Triggered by the Moderna COVID-19 Vaccine. Allergy Rhinol (Providence). 2021;12:21526567211026270. doi:10.1177/21526567211026271
8. Magerl M, Altrichter S, Borzova E, et al. The definition, diagnostic testing, and management of chronic inducible urticarias – The EAACI/GA2LEN/EDF/UNEV consensus recommendations 2016 update and revision. Allergy. 2016;71(6):780-802. doi:10.1111/all.12884
9. Wassef C, Laureano A, Schwartz RA. Aquagenic Urticaria: A Perplexing Physical Phenomenon. Acta Dermatovenerologica Croatica. 2017;25(3):234-237.
10. Rujitharanawong C, Kulthanan K, Tuchinda P, Chularojanamontri L, Metz M, Maurer M. A Systematic Review of Aquagenic Urticaria-Subgroups and Treatment Options. J Allergy Clin Immunol Pract. Published online May 6, 2022:S2213-2198(22)00477-9. doi:10.1016/j.jaip.2022.04.033
11. Hamady A, Lee J, Loboda ZA. Waning antibody responses in COVID-19: what can we learn from the analysis of other coronaviruses? Infection. 2022;50(1):11-25. doi:10.1007/s15010-021-01664-z
12. Prasad S, McMahon DE, Tyagi A, et al. Cutaneous reactions following booster dose administration of COVID-19 mRNA vaccine: A first look from the American Academy of Dermatology/International League of Dermatologic Societies registry. JAAD International. 2022;8:49-51. doi:10.1016/j.jdin.2022.04.004
13. Singh R, Ali R, Prasad S, Chen ST, Blumenthal K, Freeman EE. Proposing a standardized assessment of COVID-19 vaccine-associated cutaneous reactions. Journal of the American Academy of Dermatology. Published online May 13, 2022. doi:10.1016/j.jaad.2022.05.011
14. Anvari S, Samarakoon U, Fu X, et al. Urticaria and/or angioedema secondary to mRNA COVID-19 vaccines: Updates from a United States case registry. Allergy. doi:10.1111/all.15447
15. Banerji A, Wickner PG, Saff R, et al. mRNA Vaccines to Prevent COVID-19 Disease and Reported Allergic Reactions: Current Evidence and Suggested Approach. The Journal of Allergy and Clinical Immunology: In Practice. 2021;9(4):1423-1437. doi:10.1016/j.jaip.2020.12.047
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.
Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.
Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.